These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25061430)

  • 41. Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data.
    Bloomgren G; Sperling B; Cushing K; Wenten M
    Ther Clin Risk Manag; 2012; 8():313-21. PubMed ID: 22767995
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis.
    Correia I; Marques IB; Sousa M; Batista S; Ferreira R; Nunes C; Macário C; Cunha L; Sousa L
    J Clin Neurosci; 2016 Nov; 33():73-78. PubMed ID: 27542939
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rebif(®) Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis.
    Bandari D; Wynn D; Miller T; Singer B; Wray S; Bennett R; Hayward B; Dangond F;
    Mult Scler Relat Disord; 2013 Jan; 2(1):45-56. PubMed ID: 25877454
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Disease-modifying Therapies for Multiple Sclerosis.
    Corboy JR; Goodin DS; Frohman EM
    Curr Treat Options Neurol; 2003 Jan; 5(1):35-54. PubMed ID: 12521562
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis.
    Macías-Islas MA; Soria-Cedillo IF; Velazquez-Quintana M; Rivera VM; Baca-Muro VI; Lemus-Carmona EA; Chiquete E
    Acta Neurol Belg; 2013 Dec; 113(4):415-20. PubMed ID: 23670405
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antidepressant Drug Treatment in Association with Multiple Sclerosis Disease-Modifying Therapy: Using Explorys in the MS Population.
    Mirsky MM; Marrie RA; Rae-Grant A
    Int J MS Care; 2016; 18(6):305-310. PubMed ID: 27999525
    [No Abstract]   [Full Text] [Related]  

  • 47. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.
    Clanet M; Kappos L; Hartung HP; Hohlfeld R;
    Mult Scler; 2004 Apr; 10(2):139-44. PubMed ID: 15124757
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts.
    Castelli-Haley J; Oleen-Burkey MA; Lage MJ; Johnson K
    J Med Econ; 2010; 13(3):464-71. PubMed ID: 20662760
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis.
    Devonshire V; Lapierre Y; Macdonell R; Ramo-Tello C; Patti F; Fontoura P; Suchet L; Hyde R; Balla I; Frohman EM; Kieseier BC;
    Eur J Neurol; 2011 Jan; 18(1):69-77. PubMed ID: 20561039
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis.
    Singer B; Wray S; Miller T; Cascione M; Gupta A; Pardo G; Watsky E; Hayward B; Mercer B; Dangond F
    Mult Scler Relat Disord; 2012 Apr; 1(2):87-94. PubMed ID: 25876936
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
    Singer B; Bandari D; Cascione M; LaGanke C; Huddlestone J; Bennett R; Dangond F;
    BMC Neurol; 2012 Dec; 12():154. PubMed ID: 23216674
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum interferon beta-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients.
    Khan OA; Dhib-Jalbut SS
    Neurology; 1998 Sep; 51(3):738-42. PubMed ID: 9748019
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a.
    Limmroth V; Gerbershagen K
    Expert Opin Drug Deliv; 2014 Dec; 11(12):1969-78. PubMed ID: 25255732
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interferon-beta injection site reactions in patients with multiple sclerosis.
    Maurelli M; Bergamaschi R; Antonini A; Fargnoli MC; Puma E; Mallucci G; Totaro R; Girolomoni G
    J Dermatolog Treat; 2018 Dec; 29(8):831-834. PubMed ID: 29671656
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
    Calkwood J; Cree B; Crayton H; Kantor D; Steingo B; Barbato L; Hashmonay R; Agashivala N; McCague K; Tenenbaum N; Edwards K
    BMC Neurol; 2014 Nov; 14():220. PubMed ID: 25424122
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
    Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
    Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P; Calabrese M; Biasi G; Gallo P
    J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.
    Vollmer TL; Phillips JT; Goodman AD; Agius MA; Libonati MA; Giacchino JL; Grundy JS
    Mult Scler; 2004 Oct; 10(5):511-20. PubMed ID: 15471366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study.
    Saiz A; Mora S; Blanco J;
    Neurologia; 2015 May; 30(4):214-22. PubMed ID: 24484756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.